Revolution Medicines, Inc. - Common Stock — Financial Statistics (NASDAQ:RVMD) | MetaTrader

Open full chart

News

10 Health Care Stocks With Whale Alerts In Today’s Session

Stock Market Today: S&P 500 Slips as Oil Spikes 5%, 10-Year Yields Near 5.35%

RBC Capital Maintains Outperform on Revolution Medicines, Raises Price Target to $259

Truist Securities Maintains Buy on Revolution Medicines, Raises Price Target to $240

Biotech Stocks Tumble, With Recent Winners Moderna, Vaxcyte Among The Biggest Losers

Revolution Medicines Begins Treating Patients In RASolute 309, Global, Randomized Phase 3 Clinical Trial Evaluating Combination Of RASONQUE And Zoldonrasib As First-Line Treatment In Adult Patients With Metastatic RAS G12D PDAC

3 Overlooked Vanguard ETFs with 30%+ Upside - TipRanks.com

Revolution Medicines: Priced For A Label The Trial Didn't Test; Hold (NASDAQ:RVMD)

Brookline Capital Initiates Coverage On Revolution Medicines with Buy Rating, Announces Price Target of $318

This Cancer Drug Is Already Working. Now Its Nvidia-Backed Maker Is Going Public: Here’s What You Need to Know About Its IPO

Goldman Sachs Reinstates Buy on Revolution Medicines, Announces $267 Price Target

Here's How Much $1000 Invested In Revolution Medicines 5 Years Ago Would Be Worth Today